Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

被引:317
作者
Keegan, M
König, F
McClelland, R
Brück, W
Morales, Y
Bitsch, A
Panitch, H
Lassmann, H
Weinshenker, B
Rodriguez, M
Parisi, J
Lucchinetti, CF [1 ]
机构
[1] Mayo Clin Coll Med, Dept Neurol, Rochester, MN 55905 USA
[2] Mayo Clin Coll Med, Dept Hlth Sci Res, Rochester, MN 55905 USA
[3] Mayo Clin Coll Med, Dept Lab Med & Pathol, Rochester, MN 55905 USA
[4] Mayo Clin Coll Med, Dept Immunol, Rochester, MN 55905 USA
[5] Mayo Clin Coll Med, Mayo Grad Sch, Rochester, MN 55905 USA
[6] Inst Neuropathol, Gottingen, Germany
[7] Ruppiner Kliniken GmbH, Neuruppin, Germany
[8] Univ Vermont, Burlington, VT USA
[9] Univ Vienna, Brain Res Inst, Vienna, Austria
关键词
D O I
10.1016/S0140-6736(05)67102-4
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Early, active multiple sclerosis lesions show four immunopathological patterns of demyelination. Although these patterns differ between patients, multiple active lesions from a given patient have an identical pattern, which suggests pathogenic heterogeneity. Therapeutic plasma exchange (TPE) has been successfully used to treat fulminant demyelinating attacks unresponsive to steroids. We postulated that patients with pattern II would be more likely to improve after TPE than those with other patterns since pattern II lesions are distinguished by prominent immunoglobulin deposition and complement activation. We retrospectively studied 19 patients treated with TPE for an attack of fulminant CNS inflammatory demyelinating disease. All patients with pattern II (n=10), but none with pattern I (n=3) or pattern III (n=6), achieved moderate to substantial functional neurological improvement after TPE (p<0.0001). Patients with multiple sclerosis with pattern II pathology are more likely to respond favourably to TPE than are patients with patterns I or III.
引用
收藏
页码:579 / 582
页数:4
相关论文
共 10 条
[1]
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event [J].
Berger, T ;
Rubner, P ;
Schautzer, F ;
Egg, R ;
Ulmer, H ;
Mayringer, I ;
Dilitz, E ;
Deisenhammer, F ;
Reindl, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (02) :139-145
[2]
B cells and antibodies in CNS demyelinating disease [J].
Cross, AH ;
Trotter, JL ;
Lyons, JA .
JOURNAL OF NEUROIMMUNOLOGY, 2001, 112 (1-2) :1-14
[3]
Plasma exchange for severe attacks of CNS demyelination: Predictors of response [J].
Keegan, M ;
Pineda, AA ;
McClelland, RL ;
Darby, CH ;
Rodriguez, M ;
Weinshenker, BG .
NEUROLOGY, 2002, 58 (01) :143-146
[4]
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis [J].
Lennon, VA ;
Wingerchuk, DM ;
Kryzer, TJ ;
Pittock, SJ ;
Lucchinetti, CF ;
Fujihara, K ;
Nakashima, I ;
Weinshenker, BG .
LANCET, 2004, 364 (9451) :2106-2112
[5]
Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO
[6]
2-Q
[7]
PITTOCK SJ, IN PRESS J NEUROL NE
[8]
WEINSHENKER B, 2001, MULTIPLE SCLEROSIS T, P267
[9]
Weinshenker BG, 1999, ANN NEUROL, V46, P878, DOI 10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO
[10]
2-Q